Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445147 | 0.82 | ALOX5 (0.39) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL988364 | 0.73 | LMNA (0.43) | CA1CA2CA7CA14 | |
| SCHEMBL8354255 | 0.72 | CHRNB2 (0.38) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6323126 | 0.72 | ALOX5 (0.35) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6329644 | 0.72 | ALOX5 (0.38) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6330663 | 0.72 | GRIA4 (0.36) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL31111546 | 0.72 | LMNA (0.42) | CA1CA2CA7CA14 | |
| SCHEMBL8356434 | 0.71 | CHRNB2 (0.37) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3465616 | 0.71 | — | — | |
| SCHEMBL2009597 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-0939629-A4 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | ALOX5 650/4885CHRNB2 4880/4885CHRNB4 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.